2017-05-16 13:52:32 UTC

Advent of Biosimilar Products in US GI Practice

June 1, 2017

Biosimilars have become a hot topic, but are you prepared to talk to your patients about optimum use?

Biosimilars are making gains in the U.S. drug market, accounting for about 1 percent of prescriptions written and 28 percent of drug spending.

Despite this recent growth, many patients are hesitant to be switched onto biosimilars. Among patients who heard of but are not being treated with biosimilars, 47 percent worry about the safety profile of the agents and 56 percent think the lower cost of biosimilars should not come before their safety and efficacy. AGA agrees with that sentiment, which is why we recently submitted recommendations to FDA to ensure future guidance on interchangeable biosimilars keeps patients and physicians top of mind, not insurance companies. 

To best answer your patients’ questions, you need to stay up-to-date on biosimilars. Gary Lichtenstein, MD, AGAF, Brian Feagan, MD, and David Rubin, MD, AGAF, explored biosimilars during a session at DDW® 2017. You can read a session recap on the DDW Blog

Dr. Lichtenstein goes into further details in the DDW TV interview below.

As Dr. Lichtenstein mentions, AGA has convened a task force to provide education to GIs on the use of biosimilars. Stay tuned for additional information in the upcoming months.

More on IBD

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders and get inspired to improve patient care.

IBD in the ED

Aug. 17, 2017

Emergency visits are a costly component of IBD care, but these factors can help ward off flares with dire complications

Treating HCV in Incarcerated Populations Key to Disease Elimination

Aug. 17, 2017

Infection rates range from 9.6% to 41.1%